Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | PREP | P48147 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487292 | 1.00 | HTR2C (0.52) | HTR2CPREPNPSR1FKBP1AALDH1A1 | |
| SCHEMBL3017853 | 1.00 | HTR2C (0.52) | HTR2CPREPNPSR1FKBP1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL7013165 | 0.99 | HTR2C (0.51) | HTR2CPREPNPSR1FKBP1AALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL30253251 | 0.94 | HTR2C (0.46) | HTR2CPREPNPSR1FKBP1AALDH1A1 | |
| SCHEMBL4674934 | 0.91 | HTR2C (0.52) | HTR2CPREPNPSR1FKBP1ANPC1 | |
| SCHEMBL27736628 | 0.89 | HTR2C (0.51) | HTR2CPREPNPSR1FKBP1ATSHR | |
| SCHEMBL27757498 | 0.89 | HTR2C (0.51) | HTR2CPREPNPSR1FKBP1ATSHR | |
| SCHEMBL20299652 | 0.89 | FKBP1A (0.52) | HTR2CPREPNPSR1FKBP1AALDH1A1 | |
| SCHEMBL7251746 | 0.88 | HTR2C (0.53) | HTR2CPREPNPSR1NPC1RAB9A | |
| SCHEMBL8220722 | 0.88 | HTR2C (0.53) | HTR2CPREPNPSR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2830624-B1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9133147-B2 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133147-B2 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150038498-A1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME LLC | 2015-02-05 | — | — | US | disclosed |
| US-20150038498-A1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME LLC | 2015-02-05 | — | — | US | disclosed |
| EP-2830624-A1 | THROMBIN INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-02-04 | — | — | EP | disclosed |
| WO-2013148478-A1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013148478-A1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-10-03 | — | — | WO | disclosed |
| US-6911442-B1 | Quinoline derivatives as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-06-28 | — | — | US | disclosed |
| EP-1187828-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-04-21 | — | — | EP | disclosed |
| EP-1187828-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000078748-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038498-A1 | THROMBIN INHIBITORS | F3, F2, CFH | HTR2C 924/4885PREP 2788/4885NPSR1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.